Allergen immunotherapy: Much more than a shot in the dark

摘要

Allergic rhinitis (AR) is a prevalent disease that can significantly affect the well-being, productivity, and quality of life of children and adults. Allergen immunotherapy has been used to effectively treat AR for more than 100 years and is unique among available therapeutic interventions in its ability to modify AR's course. In addition, there is evidence that it prevents new sensitizations. Thus, it is important to establish whether subcu-taneously administered allergy immunotherapy (AIT) is associated with lower health care costs. In this issue, Hankin et al examine its cost benefits in adults and children.